CN105535177A - 一种治疗脑萎缩的药物组合物及其制备方法 - Google Patents
一种治疗脑萎缩的药物组合物及其制备方法 Download PDFInfo
- Publication number
- CN105535177A CN105535177A CN201610047233.6A CN201610047233A CN105535177A CN 105535177 A CN105535177 A CN 105535177A CN 201610047233 A CN201610047233 A CN 201610047233A CN 105535177 A CN105535177 A CN 105535177A
- Authority
- CN
- China
- Prior art keywords
- weight portion
- pharmaceutical composition
- ethanol
- percent concentration
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 title claims abstract description 61
- 239000000203 mixture Substances 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- 229940079593 drug Drugs 0.000 title claims description 41
- MIBATSHDJRIUJK-ROJLCIKYSA-N Neferine Chemical compound C1=CC(OC)=CC=C1C[C@@H]1C2=CC(OC=3C(=CC=C(C[C@@H]4C5=CC(OC)=C(OC)C=C5CCN4C)C=3)O)=C(OC)C=C2CCN1C MIBATSHDJRIUJK-ROJLCIKYSA-N 0.000 claims abstract description 27
- FNGGIPWAZSFKCN-ACRUOGEOSA-N tabersonine Chemical compound N1C2=CC=CC=C2[C@]2([C@H]34)C1=C(C(=O)OC)C[C@]3(CC)C=CCN4CC2 FNGGIPWAZSFKCN-ACRUOGEOSA-N 0.000 claims abstract description 27
- JSLDLCGKZDUQSH-RTBUJCADSA-N 19-epivindolinine Natural products O=C(OC)[C@H]1[C@@]23[C@H](C)[C@]4([C@@H]5N(CC=C4)CC[C@]25c2c(N3)cccc2)C1 JSLDLCGKZDUQSH-RTBUJCADSA-N 0.000 claims abstract description 26
- NFHFNBFYZIJLKZ-UHFFFAOYSA-N Asarinin Natural products CC1(OCC2C1COC2c3ccc4OCOc4c3)c5ccc6OCOc6c5 NFHFNBFYZIJLKZ-UHFFFAOYSA-N 0.000 claims abstract description 26
- KILNDJCLJBOWAN-UHFFFAOYSA-N Tabersonine Natural products CCC12CC(=C3N(C)c4cc(OC)ccc4C35CCN(CC=C1)C25)C(=O)OC KILNDJCLJBOWAN-UHFFFAOYSA-N 0.000 claims abstract description 26
- PEYUIKBAABKQKQ-UHFFFAOYSA-N epiasarinin Natural products C1=C2OCOC2=CC(C2OCC3C2COC3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-UHFFFAOYSA-N 0.000 claims abstract description 26
- FNGGIPWAZSFKCN-UHFFFAOYSA-N xi-tabersonine Natural products N1C2=CC=CC=C2C2(C34)C1=C(C(=O)OC)CC3(CC)C=CCN4CC2 FNGGIPWAZSFKCN-UHFFFAOYSA-N 0.000 claims abstract description 26
- 241001495640 Galium boreale Species 0.000 claims abstract description 20
- PEYUIKBAABKQKQ-AFHBHXEDSA-N (+)-sesamin Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-AFHBHXEDSA-N 0.000 claims abstract 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 112
- 239000008194 pharmaceutical composition Substances 0.000 claims description 57
- 208000024806 Brain atrophy Diseases 0.000 claims description 54
- 239000000284 extract Substances 0.000 claims description 35
- 230000000274 adsorptive effect Effects 0.000 claims description 28
- 238000000605 extraction Methods 0.000 claims description 28
- 229920005989 resin Polymers 0.000 claims description 28
- 239000011347 resin Substances 0.000 claims description 28
- 239000002904 solvent Substances 0.000 claims description 28
- 241000124033 Salix Species 0.000 claims description 23
- 238000002156 mixing Methods 0.000 claims description 18
- 239000007788 liquid Substances 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 230000001476 alcoholic effect Effects 0.000 claims description 14
- 239000012141 concentrate Substances 0.000 claims description 14
- 238000001035 drying Methods 0.000 claims description 14
- 238000010828 elution Methods 0.000 claims description 14
- 238000010438 heat treatment Methods 0.000 claims description 8
- 230000002879 macerating effect Effects 0.000 claims description 7
- 239000006187 pill Substances 0.000 claims description 7
- 238000010992 reflux Methods 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 238000007796 conventional method Methods 0.000 claims description 4
- MIBATSHDJRIUJK-UHFFFAOYSA-N Neferine Natural products C1=CC(OC)=CC=C1CC1C2=CC(OC=3C(=CC=C(CC4C5=CC(OC)=C(OC)C=C5CCN4C)C=3)O)=C(OC)C=C2CCN1C MIBATSHDJRIUJK-UHFFFAOYSA-N 0.000 abstract description 3
- 238000005516 engineering process Methods 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 2
- 244000025254 Cannabis sativa Species 0.000 abstract 2
- 241001083574 Thyrocarpus sampsonii Species 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- PEYUIKBAABKQKQ-WZBLMQSHSA-N 5-[(3r,3ar,6s,6ar)-3-(1,3-benzodioxol-5-yl)-1,3,3a,4,6,6a-hexahydrofuro[3,4-c]furan-6-yl]-1,3-benzodioxole Chemical compound C1=C2OCOC2=CC([C@@H]2OC[C@H]3[C@@H]2CO[C@@H]3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-WZBLMQSHSA-N 0.000 description 20
- 201000010099 disease Diseases 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 230000007812 deficiency Effects 0.000 description 10
- 210000004556 brain Anatomy 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 7
- 208000037920 primary disease Diseases 0.000 description 6
- 206010003694 Atrophy Diseases 0.000 description 4
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 4
- 206010044565 Tremor Diseases 0.000 description 4
- 230000037444 atrophy Effects 0.000 description 4
- 208000002173 dizziness Diseases 0.000 description 4
- 239000003172 expectorant agent Substances 0.000 description 4
- 230000003419 expectorant effect Effects 0.000 description 4
- 206010022437 insomnia Diseases 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 210000004209 hair Anatomy 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 241000609218 Amsonia elliptica Species 0.000 description 2
- 206010008096 Cerebral atrophy Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010011878 Deafness Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010013887 Dysarthria Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- 208000021642 Muscular disease Diseases 0.000 description 2
- 201000009623 Myopathy Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000031971 Yin Deficiency Diseases 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 201000007201 aphasia Diseases 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
- 230000021595 spermatogenesis Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- 241000227146 Agarista salicifolia Species 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241001072256 Boraginaceae Species 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 240000008384 Capsicum annuum var. annuum Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010008027 Cerebellar atrophy Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000006479 Cyme Species 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 240000005702 Galium aparine Species 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010024774 Localised infection Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 240000002834 Paulownia tomentosa Species 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 244000304393 Phlox paniculata Species 0.000 description 1
- 241001529246 Platymiscium Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 240000004460 Tanacetum coccineum Species 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 244000131415 Zanthoxylum piperitum Species 0.000 description 1
- 235000008853 Zanthoxylum piperitum Nutrition 0.000 description 1
- ROVGZAWFACYCSP-MQBLHHJJSA-N [2-methyl-4-oxo-3-[(2z)-penta-2,4-dienyl]cyclopent-2-en-1-yl] (1r,3r)-2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropane-1-carboxylate Chemical compound CC1(C)[C@H](C=C(C)C)[C@H]1C(=O)OC1C(C)=C(C\C=C/C=C)C(=O)C1 ROVGZAWFACYCSP-MQBLHHJJSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- PMIRJPWEIZTLEG-KTGNWYGMSA-N alstonerine Chemical compound CN1C2=CC=CC=C2C(C2)=C1[C@H]1N(C)[C@@H]2[C@H](COC=C2C(C)=O)[C@H]2C1 PMIRJPWEIZTLEG-KTGNWYGMSA-N 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- -1 and dry Substances 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000023513 hiccough Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229940015367 pyrethrum Drugs 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 208000011726 slow pulse Diseases 0.000 description 1
- 208000026473 slurred speech Diseases 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000003813 thin hair Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种治疗脑萎缩的药物组合物及其制备方法,本发明药物组合物是以凤蝶色素II、砧草、盾果草、甲基莲心碱、细辛脂素、柳叶水甘草碱为原料药,配比而成,可按常规制剂工艺制成各种剂型,治疗脑萎缩疗效显著。
Description
技术领域
本发明属于中药技术领域,尤其涉及一种治疗脑萎缩的药物组合物及其制备方法。
背景技术
脑萎缩是指由于各种原因导致脑组织本身发生器质性病变而产生萎缩的一类神经精神性疾病。脑萎缩包括小儿脑萎缩、成人脑萎缩。以老年人多见。萎缩在临床最主要的症状是痴呆,尤其是老年人易引起老年痴呆症。脑萎缩属中医“痴呆”、“健忘”、“眩晕”、“痿证”、“震颤”等范畴。中医认为本病虽病位在脑,但与各脏腑功能密切相关,病理机制属本虚标实。
脑萎缩成年人发病:多发生于50岁以上,病程可达数年至数十年,男性多于女性,脑萎缩有弥漫性脑萎缩(包括皮层萎缩、小脑萎缩及皮层、小脑、脑干萎缩)及局限性脑萎缩(多见于局限性脑器质性病变后如外伤、血管病、颅内局限性感染后等)。因其病因复杂,起病缓慢,不易被发觉,病程长,进展缓慢,而且可能逐渐加重,影响患者的正常生活和工作。及早发现、积极适当的控制病情和进一步治疗具有重要意义。患者在疾病早期没有明显表现,故一般发现时其已经处于晚期。此时患者的脑部组织已经表现为明显缩小的情况,此时西医进行治疗的效果不理想。中医对此疾病并没有描述,但其症状和震颤、痿证、眩晕、虚劳有相关性,属于此类疾病的范畴内。其发病机理为久病气虚、肝肾不足、心神失养、脑髓不充;或年老肾衰,不能生精充髓,髓海空虚,脑窍失荣;或肝木失疏,克伐脾土,脾失健运,水谷不能化生精微,气血不能上荣于脑,反生痰浊,蒙蔽清窍而致本病。本病的治疗,目前现代医学只能治疗其精神症状,难以治愈其“髓海不足”与“脑髓渐空”的特点。综观本病,成因有虚实两端,本虚而标实。脑萎缩发病隐匿,早期症状不明显,对预防和早期诊断带来困难,脑萎缩属于慢性病,久病入络,阴阳俱虚,兼夹证复杂,其证型的复杂、多变性给临床辨证治疗带来困难,对脑萎缩高危人群进行早期筛查,干预,及早发现及控制病情,治病求本是中医治疗的一大特点,对于本病的治疗,针对其主要病理变化进行辩证施治尤为重要,治疗失败的原因主要是由于本病的表现错综复杂,临床上抓不住主要病因病机所致。因此,必须详细分析病因、病史、症状、舌脉诸项,要透过现象看本质,否则会失去中医治病的原则和意义。
凤蝶色素II(PapiliochromeII):CAS号68335-21-7,分子式C21H26N4O6,分子量430.46。
砧草:为茜草科拉拉藤属植物北方拉拉藤GaliumborealeL.的全草。秋季采收,切段晒干。【性味】苦;寒。【功能主治】清热解毒;祛风活血。主肺炎咳嗽;肾炎水肿;腰腿疼痛;妇女经闭;痛经;带下;疮癣。【化学成份】含精油、香豆精类、黄酮类以及蒽醌类化合物。【原植物形态】北方拉拉藤,多年生直立草本,高20-50cm。茎具四棱,有分枝,近无毛或节部有微毛。叶4片轮生;无柄;叶片线状披针形,长1-3.5cm,宽2-4mm,先端钝,基部阔楔形或近圆形,边缘略反卷。基出脉3条,除边缘有微毛外,二面无毛。聚伞花序顶生,或在枝顶结成带叶的圆锥花序状;花密,小,黄白色;小花梗长3-5mm;萼片4,椭圆状卵形,有疏毛,先端短渐尖;雄蕊4,与萼片互生;子房下位,近球形,花柱2裂至近基部。果实球形,小,黑色,密被白色钩毛。花期6-8月,果期7-9月。收载于中药大辞典。
盾果草:紫草科盾果草属植物盾果草ThyrocarpussampsoniiHance的全草。4~6月采全草,晒干。【性味】苦;凉。【归经】心;大肠经。【功能主治】清热解毒消肿。主痈肿;疔疮;咽喉疼痛;泄泻;痢疾。【性状】茎较细,1至数条,圆柱形,长10-30cm,表面枯绿色,具灰白色糙毛,质脆易折断,断面白色。基生叶丛生,皱缩卷曲,湿润展开后,匙形,具柄,长3.5-19cm,宽1-5cm,枯绿色或深绿色,两面均具灰白色粗毛,茎生叶较小,无柄。叶片稍厚。有时可见蓝或紫色小花。或有两层碗状突起的小坚果,基顶部外层有直立的齿轮,内层紧贴边缘。气微味微苦。收载于中药大辞典。
甲基莲心碱(Neferine):CAS号2292-16-2,分子式C38H44N2O6,分子量624.77。【药理作用】抗心律失常;抗高血压(血管舒张,独立血管内皮);抑制癌症的促进剂;钙拮抗(10~40umol/L,抑制ET-l引起的Ca2±浓度增加);抑制心肌;血小板聚集抑制剂(抑制外钙内流和血小板内钙的释放)。【成分来源】莲子心Nelumbonucifera。
细辛脂素(Asarinin):CAS号133-05-1,分子式C20H18O6,分子量354.35。【药理作用】对除虫菊素有增敏作用。【成分来源】阿诺提花椒Zanthaxylumarnottianum,得卡瑞花椒Zanthoxylumdecatyi,胡椒花椒Zanthoxylumpiperitum,毛泡桐Paulowniatomentosa,细辛A.sarum.sieboldii。
柳叶水甘草碱(Tabersonine):CAS号4429-63-4,分子式C21H24N2O2,分子量336.43。【药理作用】猫体试验,有降压作用,强度为利血平的25%。【成分来源】夹竹桃植物柳叶水甘草AmsoniatabernaemontanaWalt.(=A.salicifolia)叶,长春花Cantharanthusroseus(L.)G.Don种子,椭圆叶水甘草AmsoniaellipticaRoem.EtSchult.种子,非洲沃坎加树VoacangoafricanaStapf种子。
4个原料药化学结构:
细辛脂素(Asarinin)凤蝶色素II(PapiliochromeII)
甲基莲心碱(Neferine)柳叶水甘草碱(Tabersonine)。
发明内容
本发明的目的是克服背景技术的不足,提供一种有效治疗脑萎缩的药物组合物及其制备方法。
本发明是采用如下技术方案实现的:
制成该治疗脑萎缩的药物组合物的原料药的组成和重量份为:
凤蝶色素II20-40重量份砧草4370-4390重量份盾果草3600-3700重量份甲基莲心碱40-90重量份细辛脂素5-7重量份柳叶水甘草碱10-18重量份。
优选的用于治疗脑萎缩的药物组合物,是由如下重量份的原料药组成:
凤蝶色素II30重量份砧草4380重量份盾果草3650重量份甲基莲心碱65重量份细辛脂素6重量份柳叶水甘草碱14重量份。
一种治疗脑萎缩的药物组合物,其特征在于药物组合物可以采用制剂学的常规方法制备成片剂或胶囊剂或滴丸。
一种治疗脑萎缩的药物组合物,其特征在于药物组合物与化学药或中药组成的治疗脑萎缩药物。
一种治疗脑萎缩的药物组合物的制备方法,其特征在于按如下步骤制备:
原料药的组成和重量份为:凤蝶色素II20-40重量份砧草4370-4390重量份盾果草3600-3700重量份甲基莲心碱40-90重量份细辛脂素5-7重量份柳叶水甘草碱10-18重量份;
制备方法:
(1)按原料药配比取凤蝶色素II、砧草、盾果草、甲基莲心碱、细辛脂素、柳叶水甘草碱,混匀,用重量百分比浓度21%乙醇作为溶剂,在33℃温浸提取,提取次数为17次,每次提取时间为1.5小时,每次溶剂用量为原料药总重量的22.5倍,滤过,得药渣A和提取液A,提取液A回收乙醇,浓缩至相对密度1.13,滤过,药液通过S8大孔吸附树脂柱,先用水洗脱,再用重量百分比浓度74.5%乙醇溶液洗脱S8大孔吸附树脂柱,收集重量百分比浓度74.5%乙醇洗脱液,回收乙醇,浓缩干燥,即得提取物A;
(2)取步骤(1)药渣A,用重量百分比浓度44.5%乙醇作为溶剂,加热回流提取5次,每次提取时间为1.2小时,每次溶剂用量为药渣A重量的21倍,滤过,得药渣B和提取液B,提取液B回收乙醇,浓缩至相对密度1.12,滤过,药液通过HP50大孔吸附树脂柱,先用水洗脱,再用重量百分比浓度83.5%乙醇溶液洗脱HP50大孔吸附树脂柱,收集重量百分比浓度83.5%乙醇洗脱液,回收乙醇,浓缩干燥,即得提取物B;
(3)将提取物A和提取物B混匀,即得药物组合物。
优选的一种治疗脑萎缩的药物组合物的制备方法,其特征在于按如下步骤制备:
原料药的组成和重量份为:凤蝶色素II30重量份砧草4380重量份盾果草3650重量份甲基莲心碱65重量份细辛脂素6重量份柳叶水甘草碱14重量份;
制备方法:
(1)按原料药配比取凤蝶色素II、砧草、盾果草、甲基莲心碱、细辛脂素、柳叶水甘草碱,混匀,用重量百分比浓度21%乙醇作为溶剂,在33℃温浸提取,提取次数为17次,每次提取时间为1.5小时,每次溶剂用量为原料药总重量的22.5倍,滤过,得药渣A和提取液A,提取液A回收乙醇,浓缩至相对密度1.13,滤过,药液通过S8大孔吸附树脂柱,先用水洗脱,再用重量百分比浓度74.5%乙醇溶液洗脱S8大孔吸附树脂柱,收集重量百分比浓度74.5%乙醇洗脱液,回收乙醇,浓缩干燥,即得提取物A;
(2)取步骤(1)药渣A,用重量百分比浓度44.5%乙醇作为溶剂,加热回流提取5次,每次提取时间为1.2小时,每次溶剂用量为药渣A重量的21倍,滤过,得药渣B和提取液B,提取液B回收乙醇,浓缩至相对密度1.12,滤过,药液通过HP50大孔吸附树脂柱,先用水洗脱,再用重量百分比浓度83.5%乙醇溶液洗脱HP50大孔吸附树脂柱,收集重量百分比浓度83.5%乙醇洗脱液,回收乙醇,浓缩干燥,即得提取物B;
(3)将提取物A和提取物B混匀,即得药物组合物。
一种治疗脑萎缩的药物组合物的制备方法,其特征在于药物组合物可以采用制剂学的常规方法制备成片剂或胶囊剂或滴丸。
一种治疗脑萎缩的药物组合物的制备方法,其特征在于药物组合物与化学药或中药组成治疗脑萎缩药物。
药物组合物治疗脑萎缩疗效显著。
具体实施方式
实施例1:治疗脑萎缩的药物组合物及其制备方法
治疗脑萎缩的药物组合物的原料药的组成和重量份为:凤蝶色素II30g砧草4380g盾果草3650g甲基莲心碱65g细辛脂素6g柳叶水甘草碱14g;
制备方法:
(1)按原料药配比取凤蝶色素II、砧草、盾果草、甲基莲心碱、细辛脂素、柳叶水甘草碱,混匀,用重量百分比浓度21%乙醇作为溶剂,在33℃温浸提取,提取次数为17次,每次提取时间为1.5小时,每次溶剂用量为原料药总重量的22.5倍,滤过,得药渣A和提取液A,提取液A回收乙醇,浓缩至相对密度1.13,滤过,药液通过S8大孔吸附树脂柱,先用水洗脱,再用重量百分比浓度74.5%乙醇溶液洗脱S8大孔吸附树脂柱,收集重量百分比浓度74.5%乙醇洗脱液,回收乙醇,浓缩干燥,即得提取物A;
(2)取步骤(1)药渣A,用重量百分比浓度44.5%乙醇作为溶剂,加热回流提取5次,每次提取时间为1.2小时,每次溶剂用量为药渣A重量的21倍,滤过,得药渣B和提取液B,提取液B回收乙醇,浓缩至相对密度1.12,滤过,药液通过HP50大孔吸附树脂柱,先用水洗脱,再用重量百分比浓度83.5%乙醇溶液洗脱HP50大孔吸附树脂柱,收集重量百分比浓度83.5%乙醇洗脱液,回收乙醇,浓缩干燥,即得提取物B;
(3)将提取物A和提取物B混匀,即得药物组合物。
实施例2:治疗脑萎缩的药物组合物及其制备方法
治疗脑萎缩的药物组合物的原料药的组成和重量份为:凤蝶色素II20g砧草4390g盾果草3600g甲基莲心碱90g细辛脂素5g柳叶水甘草碱18g;
制备方法:
(1)按原料药配比取凤蝶色素II、砧草、盾果草、甲基莲心碱、细辛脂素、柳叶水甘草碱,混匀,用重量百分比浓度21%乙醇作为溶剂,在33℃温浸提取,提取次数为17次,每次提取时间为1.5小时,每次溶剂用量为原料药总重量的22.5倍,滤过,得药渣A和提取液A,提取液A回收乙醇,浓缩至相对密度1.13,滤过,药液通过S8大孔吸附树脂柱,先用水洗脱,再用重量百分比浓度74.5%乙醇溶液洗脱S8大孔吸附树脂柱,收集重量百分比浓度74.5%乙醇洗脱液,回收乙醇,浓缩干燥,即得提取物A;
(2)取步骤(1)药渣A,用重量百分比浓度44.5%乙醇作为溶剂,加热回流提取5次,每次提取时间为1.2小时,每次溶剂用量为药渣A重量的21倍,滤过,得药渣B和提取液B,提取液B回收乙醇,浓缩至相对密度1.12,滤过,药液通过HP50大孔吸附树脂柱,先用水洗脱,再用重量百分比浓度83.5%乙醇溶液洗脱HP50大孔吸附树脂柱,收集重量百分比浓度83.5%乙醇洗脱液,回收乙醇,浓缩干燥,即得提取物B;
(3)将提取物A和提取物B混匀,即得药物组合物。
实施例3:治疗脑萎缩的药物组合物及其制备方法
治疗脑萎缩的药物组合物的原料药的组成和重量份为:凤蝶色素II40g砧草4370g盾果草3700g甲基莲心碱40g细辛脂素7g柳叶水甘草碱10g;
制备方法:
(1)按原料药配比取凤蝶色素II、砧草、盾果草、甲基莲心碱、细辛脂素、柳叶水甘草碱,混匀,用重量百分比浓度21%乙醇作为溶剂,在33℃温浸提取,提取次数为17次,每次提取时间为1.5小时,每次溶剂用量为原料药总重量的22.5倍,滤过,得药渣A和提取液A,提取液A回收乙醇,浓缩至相对密度1.13,滤过,药液通过S8大孔吸附树脂柱,先用水洗脱,再用重量百分比浓度74.5%乙醇溶液洗脱S8大孔吸附树脂柱,收集重量百分比浓度74.5%乙醇洗脱液,回收乙醇,浓缩干燥,即得提取物A;
(2)取步骤(1)药渣A,用重量百分比浓度44.5%乙醇作为溶剂,加热回流提取5次,每次提取时间为1.2小时,每次溶剂用量为药渣A重量的21倍,滤过,得药渣B和提取液B,提取液B回收乙醇,浓缩至相对密度1.12,滤过,药液通过HP50大孔吸附树脂柱,先用水洗脱,再用重量百分比浓度83.5%乙醇溶液洗脱HP50大孔吸附树脂柱,收集重量百分比浓度83.5%乙醇洗脱液,回收乙醇,浓缩干燥,即得提取物B;
(3)将提取物A和提取物B混匀,即得药物组合物。
实施例4:片剂的制备
取实施例1药物组合物244g,加入淀粉144g,混匀,制粒,干燥,加微晶纤维素24g,硬脂酸镁4g,混匀,压制成1000片,即得药物组合物片剂。
实施例5:胶囊的制备
取实施例2药物组合物144g,加入淀粉144g,混匀,制粒,干燥,整粒,加入适量硬脂酸镁,混匀,装胶囊1000粒,即得药物组合物胶囊。
实施例6:滴丸的制备
称取聚乙二醇6000144g水浴(80℃)加热煮熔,加入实施例3药物组合物14g,充分搅拌均匀,以液体石蜡为冷却剂,置玻璃管(4*80cm)中,冷却温度为4℃,滴口内外径为7.0/2.0(mm/mm),滴口距液面为1.4cm,滴速以每分44滴为最佳条件,用棉布吸干滴丸表面的冷凝剂,即得药物组合物滴丸。
实施例7:治疗脑萎缩的药物组合物
治疗脑萎缩的药物组合物的原料药的组成和重量份为:
凤蝶色素II28重量份甲基莲心碱4重量份细辛脂素50重量份柳叶水甘草碱15重量份。
实施例8:治疗脑萎缩的药物组合物
治疗脑萎缩的药物组合物的原料药的组成和重量份为:
凤蝶色素II30重量份甲基莲心碱42重量份细辛脂素5重量份柳叶水甘草碱18重量份。
实施例9:治疗脑萎缩的药物组合物
治疗脑萎缩的药物组合物的原料药的组成和重量份为:
凤蝶色素II23重量份甲基莲心碱45重量份细辛脂素3重量份柳叶水甘草碱110重量份。
实验例1:治疗脑萎缩的试验研究
1对象与方法
1.1一般资料
2011年4月-2012年5月通过中医辨证论治的措施对31例脑萎缩患者进行治疗,其中16例患者为男性,15例患者为女性,患者疾病的病程为5个月-6年。头部CT扫描示:脑回变窄、脑室扩大,脑沟增宽。
1.2方法
所有患者均进行中医辩证论治进行治疗。分为痰热上扰、痰浊阻滞、气滞血瘀、心脾两虚、肝肾阴虚五型,给予其针对的药物组合物进行治疗。
1.2.1患者为痰热上扰型脑萎缩
可有脉弦滑、苔黄而厚腻、舌红少津、口气秽臭、大便秘结、不思饮食、遗忘淡漠、语言重复、夜寐不眠、颜面潮红、急躁暴怒、执着任性、性格怪癖、神志呆痴等临床表现。
患者服用药物组合物(实施例1药物组合物批号20101124),每次0.5g,一日3次。
1.2.2患者为痰浊阻滞型脑萎缩
患者可有脉濡滑、苔白腻、齿龈、舌质淡、口泛痰涎、双手震颤、步态不稳、胸闷不饥、言语不清、失眠、头晕、气短、心悸、记忆衰退等临床表现。
患者服用药物组合物(实施例2药物组合物批号20101123),每次0.5g,一日3次。
1.2.3患者为气滞血瘀型脑萎缩
患者可有脉弦细、苔薄白、舌质黯红、大便秘结、口齿不清、易怒、烦躁、偏瘫、震颤、行动迟缓、耳聋失语、头痛胸闷、健忘、失眠、神情呆板等临床表现。
患者服用药物组合物(实施例3药物组合物批号20101122),每次0.5g,一日3次。
1.2.4患者为心脾两虚型脑萎缩
患者可有脉沉迟、苔白腻、舌淡体胖、下肢浮肿、小便失禁、口角流涎、纳少便溏、忧郁少动、沉默失语、神志呆疲等临床表现。
患者服用药物组合物(实施例1药物组合物批号20101124),每次0.5g,一日3次。
1.2.5患者为肝肾阴虚型脑萎缩
患者可有脉细数、舌红少津、失眠易怒、多疑善虑、视物不清、耳鸣耳聋、头痛晕眩、迟钝健忘、情绪急躁、性格固执等临床表现。治疗以益髓、填精、补肝肾为治疗原则。
患者服用药物组合物(实施例1药物组合物批号20101124),每次0.5g,一日3次。
所有患者均给予10天的治疗,中间间隔5天再进行治疗。
1.3评价指标
①治愈:经治疗后患者各项情况改善,患者生活可有进行自理,对患者进行随访,时间为2年,其疾病没有出现复发的情况。
②好转:患者的临床表现经治疗得到改善,患者生活可有进行自理,对患者随访其在6个月内有复发的情况发生。
③无效:患者自我感觉其临床表现有所改善,但对患者进行检查没有改变。
2结果
治愈14例占45.16%;好转16例占51.61%;1例患者为无效,占3.23%。
治疗的总有效率为96.77%。
治愈 | 好转 | 无效 | 总有效率(%) | |
药物组合物治疗 | 14 | 16 | 1 | 96.77 |
结果表明,药物组合物治疗脑萎缩疗效显著。
Claims (8)
1.一种治疗脑萎缩的药物组合物,其特征在于制成该药物组合物的原料药的组成和重量份为:
凤蝶色素II20-40重量份砧草4370-4390重量份盾果草3600-3700重量份甲基莲心碱40-90重量份细辛脂素5-7重量份柳叶水甘草碱10-18重量份。
2.根据权利要求1所述一种治疗脑萎缩的药物组合物,其特征在于制成该药物组合物的原料药的组成和重量份为:
凤蝶色素II30重量份砧草4380重量份盾果草3650重量份甲基莲心碱65重量份细辛脂素6重量份柳叶水甘草碱14重量份。
3.根据权利要求1所述一种治疗脑萎缩的药物组合物,其特征在于药物组合物可以采用制剂学的常规方法制备成片剂或胶囊剂或滴丸。
4.根据权利要求1所述一种治疗脑萎缩的药物组合物,其特征在于药物组合物与化学药或中药组成的治疗脑萎缩药物。
5.一种治疗脑萎缩的药物组合物的制备方法,其特征在于按如下步骤制备:
原料药的组成和重量份为:凤蝶色素II20-40重量份砧草4370-4390重量份盾果草3600-3700重量份甲基莲心碱40-90重量份细辛脂素5-7重量份柳叶水甘草碱10-18重量份;
制备方法:
(1)按原料药配比取凤蝶色素II、砧草、盾果草、甲基莲心碱、细辛脂素、柳叶水甘草碱,混匀,用重量百分比浓度21%乙醇作为溶剂,在33℃温浸提取,提取次数为17次,每次提取时间为1.5小时,每次溶剂用量为原料药总重量的22.5倍,滤过,得药渣A和提取液A,提取液A回收乙醇,浓缩至相对密度1.13,滤过,药液通过S8大孔吸附树脂柱,先用水洗脱,再用重量百分比浓度74.5%乙醇溶液洗脱S8大孔吸附树脂柱,收集重量百分比浓度74.5%乙醇洗脱液,回收乙醇,浓缩干燥,即得提取物A;
(2)取步骤(1)药渣A,用重量百分比浓度44.5%乙醇作为溶剂,加热回流提取5次,每次提取时间为1.2小时,每次溶剂用量为药渣A重量的21倍,滤过,得药渣B和提取液B,提取液B回收乙醇,浓缩至相对密度1.12,滤过,药液通过HP50大孔吸附树脂柱,先用水洗脱,再用重量百分比浓度83.5%乙醇溶液洗脱HP50大孔吸附树脂柱,收集重量百分比浓度83.5%乙醇洗脱液,回收乙醇,浓缩干燥,即得提取物B;
(3)将提取物A和提取物B混匀,即得药物组合物。
6.根据权利要求5所述一种治疗脑萎缩的药物组合物的制备方法,其特征在于按如下步骤制备:
原料药的组成和重量份为:凤蝶色素II30重量份砧草4380重量份盾果草3650重量份甲基莲心碱65重量份细辛脂素6重量份柳叶水甘草碱14重量份;
制备方法:
(1)按原料药配比取凤蝶色素II、砧草、盾果草、甲基莲心碱、细辛脂素、柳叶水甘草碱,混匀,用重量百分比浓度21%乙醇作为溶剂,在33℃温浸提取,提取次数为17次,每次提取时间为1.5小时,每次溶剂用量为原料药总重量的22.5倍,滤过,得药渣A和提取液A,提取液A回收乙醇,浓缩至相对密度1.13,滤过,药液通过S8大孔吸附树脂柱,先用水洗脱,再用重量百分比浓度74.5%乙醇溶液洗脱S8大孔吸附树脂柱,收集重量百分比浓度74.5%乙醇洗脱液,回收乙醇,浓缩干燥,即得提取物A;
(2)取步骤(1)药渣A,用重量百分比浓度44.5%乙醇作为溶剂,加热回流提取5次,每次提取时间为1.2小时,每次溶剂用量为药渣A重量的21倍,滤过,得药渣B和提取液B,提取液B回收乙醇,浓缩至相对密度1.12,滤过,药液通过HP50大孔吸附树脂柱,先用水洗脱,再用重量百分比浓度83.5%乙醇溶液洗脱HP50大孔吸附树脂柱,收集重量百分比浓度83.5%乙醇洗脱液,回收乙醇,浓缩干燥,即得提取物B;
(3)将提取物A和提取物B混匀,即得药物组合物。
7.根据权利要求5所述一种治疗脑萎缩的药物组合物的制备方法,其特征在于药物组合物可以采用制剂学的常规方法制备成片剂或胶囊剂或滴丸。
8.根据权利要求5所述一种治疗脑萎缩的药物组合物的制备方法,其特征在于药物组合物与化学药或中药组成治疗脑萎缩药物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610047233.6A CN105535177A (zh) | 2016-01-25 | 2016-01-25 | 一种治疗脑萎缩的药物组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610047233.6A CN105535177A (zh) | 2016-01-25 | 2016-01-25 | 一种治疗脑萎缩的药物组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105535177A true CN105535177A (zh) | 2016-05-04 |
Family
ID=55815095
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610047233.6A Withdrawn CN105535177A (zh) | 2016-01-25 | 2016-01-25 | 一种治疗脑萎缩的药物组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105535177A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114558010A (zh) * | 2022-03-09 | 2022-05-31 | 河南大学 | 柳叶水甘草碱在制备延长寿命的产品中的应用 |
-
2016
- 2016-01-25 CN CN201610047233.6A patent/CN105535177A/zh not_active Withdrawn
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114558010A (zh) * | 2022-03-09 | 2022-05-31 | 河南大学 | 柳叶水甘草碱在制备延长寿命的产品中的应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102772748A (zh) | 一种治疗肝郁气滞型病毒性心肌炎的中药制剂及其制备方法 | |
CN101647857B (zh) | 治疗多囊卵巢综合征的中药组合物及其制备方法 | |
CN102861287B (zh) | 一种治疗湿热下注淤血型糖尿病足的中药组合物及其制备方法 | |
CN101897821B (zh) | 一种活血通络止痛的颗粒剂及其制备和检测方法 | |
CN101095923A (zh) | 一种治疗宫外孕的中药 | |
CN104940844A (zh) | 一种治疗肝火上炎型心悸失眠的中药制剂及其制备方法 | |
CN106668348A (zh) | 用于治疗糖尿病视网膜病变的药物组合物 | |
CN105535177A (zh) | 一种治疗脑萎缩的药物组合物及其制备方法 | |
CN1679697A (zh) | 一种含有三七、瓜蒌皮、水蛭的治疗心血管疾病的中药制剂及其制备方法 | |
CN105267543A (zh) | 一种治疗气滞血瘀型原发性痛经伴黄褐斑的中药制剂 | |
CN101974011B (zh) | 一种具有药用活性的新化合物灯盏细辛酸甲酯 | |
CN105535263A (zh) | 治疗肝硬化腹水的药物组合物及其制备方法 | |
CN105477071A (zh) | 治疗脑萎缩的药物组合物及其制备方法 | |
CN104547494A (zh) | 治疗甲亢的中药组合物药酒及制备工艺 | |
CN103768412A (zh) | 一种用纯中药降低高血压高血脂的药品 | |
CN104622987B (zh) | 一种治疗慢性肝炎肝硬化的药物组合物及应用 | |
CN115531488B (zh) | 一种疏肝健脾、用于乳腺癌术后辅助治疗的组合物及其制备方法 | |
CN102228596A (zh) | 一种药物组合物及制剂及在治疗冠心病、心绞痛中的应用 | |
CN106074736A (zh) | 一种治疗脑血栓的药物组合物及其制备方法 | |
CN101974010B (zh) | 一种具有药用活性的新化合物灯盏细辛酸 | |
CN106822206A (zh) | 一种治疗神经性皮炎的药物组合物及其制备方法 | |
CN106581357A (zh) | 治疗复发性口腔溃疡的药物组合物 | |
CN105641016A (zh) | 一种治疗冠心病的药物组合物 | |
CN105030887A (zh) | 一种治疗小儿湿热型腹泻的中药制剂及其制备方法 | |
CN105535265A (zh) | 一种治疗胰腺癌的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160504 |
|
WW01 | Invention patent application withdrawn after publication |